Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth Sells 3,195 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 3,195 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $14.97, for a total value of $47,829.15. Following the completion of the sale, the chief financial officer now owns 76,486 shares of the company’s stock, valued at approximately $1,144,995.42. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, July 8th, Kory James Wentworth sold 1,758 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.95, for a total transaction of $26,282.10.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $14.72 on Wednesday. Entrada Therapeutics, Inc. has a one year low of $10.75 and a one year high of $18.17. The business’s 50 day simple moving average is $16.03 and its two-hundred day simple moving average is $14.65. The stock has a market capitalization of $496.93 million, a P/E ratio of 23.37 and a beta of -0.24.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. The company had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. Sell-side analysts expect that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds have recently modified their holdings of the company. New York State Teachers Retirement System purchased a new stake in shares of Entrada Therapeutics during the first quarter worth about $27,000. Acadian Asset Management LLC bought a new position in Entrada Therapeutics during the 1st quarter valued at approximately $79,000. Allspring Global Investments Holdings LLC lifted its holdings in Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after buying an additional 11,965 shares during the period. Rhumbline Advisers lifted its holdings in Entrada Therapeutics by 25.3% in the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after buying an additional 7,452 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $636,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analysts Set New Price Targets

TRDA has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of Entrada Therapeutics in a research note on Monday, August 26th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 14th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.